Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire - Thu Mar 19, 3:15PM CDT

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses...

GNLX : 2.56 (-3.40%)
Genelux Corporation to Participate in Upcoming Conferences GlobeNewswire - Wed Feb 18, 7:00AM CST

WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in...

GNLX : 2.56 (-3.40%)
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners GlobeNewswire - Mon Jan 12, 3:00PM CST

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 2.56 (-3.40%)
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock GlobeNewswire - Thu Jan 8, 8:13AM CST

WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten...

GNLX : 2.56 (-3.40%)
Genelux Corporation Announces Proposed Public Offering of Common Stock GlobeNewswire - Wed Jan 7, 3:01PM CST

WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a...

GNLX : 2.56 (-3.40%)
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials GlobeNewswire - Mon Jan 5, 7:00AM CST

-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment...

GNLX : 2.56 (-3.40%)
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer GlobeNewswire - Fri Jan 2, 7:00AM CST

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --   Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten,...

GNLX : 2.56 (-3.40%)
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Wed Nov 26, 2025

WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 2.56 (-3.40%)
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates GlobeNewswire - Wed Nov 5, 2025

-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026...

GNLX : 2.56 (-3.40%)
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference GlobeNewswire - Tue Sep 2, 2025

WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO...

GNLX : 2.56 (-3.40%)

Barchart Exclusives

2 Warren Buffett Dividend Stocks to Scoop Up in April Barchart - Tue Apr 21, 6:30PM CDT
Warren Buffett is known for favoring durable businesses with strong cash flows, the kind that can sustain and grow dividends over time. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.